Skip to main content

EUROpean consortium for antiCALINs as next generation high-affinity protein therapeutics

Objective

The consortium aims to develop and produce an Anticalin, a member of a novel high-affinity scaffold derived from the lipocalin protein family. The Anticalin is specific for hepcidin which is a central regulator of iron homeostasis, and will be used to antagonize hepcidin for the treatment of “anemia of chronic disease” (ACD). Anticalins are genetically modified lipocalins that can target almost any desired molecule. Unlike Immunoglobulins, they can be produced at low cost in microbial expression systems, are expected to be non immunogenic and offer therapeutic advantages where antibody effector functions are not desired. ACD, the most frequent anemia in hospitalized patients, develops in subjects suffering from infections, inflammatory and auto-immune disease, cancer and chronic kidney disease. It is often successfully treated by administering Erythropoiesis-Stimulating Agents. However, a significant number of patients are hypo- or non-responsive to ESA. Anti-hepcidin therapies, alone or together with ESAs, may improve anemia and the patients’ erythropoietic response and enable the use of no or even much lower ESA doses, avoiding the potential detrimental effects of high doses of ESA. The Consortium has already generated proof-of-concept data in an animal model with early candidates. The project aims at identifying, validating, and developing a specific, high affinity drug candidate based on the lipocalin scaffold as promising alternatives to immunoglobulins and a therapeutic approach based on the neutralization of hepcidin. Animal models will be developed and utilized to characterize pharmacokinetic and pharmacodynamic relationships, optimize dosing, to determine safety, biomarker responses and potential synergy with ESA’s. Furthermore, production processes will be optimized leading to a scalable GMP process which provides material for preclinical and clinical studies to establish the safety, tolerability, and PK/PD of an Anticalin hepcidin blocker (Phase Ia/b).

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

PIERIS PHARMACEUTICALS GMBH
Address
Lise-meitner-straße 30
85354 Freising
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 164 000
Administrative Contact
Rita Fischer (Mrs.)

Participants (10)

TECHNISCHE UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 261 600
Address
Arcisstrasse 21
80333 Muenchen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ulrike Ronchetti (Ms.)
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
EU contribution
€ 416 200
Address
Christoph Probst Platz 1
6020 Innsbruck
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Guenter Weiss (Prof.)
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 494 340
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Maarten Van Langen (Mr.)
COVANCE LABORATORIES LTD
United Kingdom
EU contribution
€ 456 800
Address
Otley Road
HG3 IPY Harrogate
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Carol Noble (Ms.)
ANTITOPE LIMITED
United Kingdom
EU contribution
€ 263 040
Address
Babraham Research Campus
CB22 3AT Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frank Carr (Dr.)
FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED
United Kingdom
EU contribution
€ 1 109 963,50
Address
Belasis Avenue
TS23 1LH Billingham
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lyons Mike (Mr.)
CORIOLIS PHARMASERVICE GMBH

Participation ended

Germany
EU contribution
€ 92 734,16
Address
Am Klopferspitz 19
82152 Martinsried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Thomas Wiggenhorn
FGK CLINICAL RESEARCH GMBH
Germany
EU contribution
€ 271 200
Address
Heimeranstrasse 35
80339 Munchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ina Ott (Mrs.)
CONSULTECH TECHNOLOGIEBERATUNG GMBH
Germany
EU contribution
€ 309 800
Address
Morgensternstrasse 24
12207 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Daniel Schubart (Dr.)
CORIOLIS PHARMA RESEARCH GMBH*
Germany
EU contribution
€ 156 625,84
Address
Am Klopferspitz 19
82152 Martinsried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Thomas Wiggenhorn